Julia Vitarello starts biotech to scale bespoke drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Julia Vitarello is forming a new biotech to scale individualized therapies after the collapse of her previous company, EveryONE Medicines.
- Mila received a custom‑designed drug for her disease‑causing mutation eight years ago, inspiring the new venture.
- FDA guidance on customized therapies was deemed insufficient by investors, contributing to EveryONE’s shutdown and the search for new capital.
Why it matters: Patients with rare mutations gain a pipeline of bespoke drugs, while investors lose on the collapsed EveryONE venture; the eight‑year gap since Mila’s treatment underscores a market finally unlocked, hastening therapy access for underserved conditions.
